Advil Congestion effort ties traffic gridlock to cold and flu misery

Share this article:
Advil Congestion effort ties traffic gridlock to cold and flu misery
Advil Congestion effort ties traffic gridlock to cold and flu misery
Don't tell the New York Post, but Pfizer is boosting bike lanes as part of an Advil promotion.

Pfizer Consumer Healthcare donated special snow removal equipment for bike lanes to Chicago, which ranks Number One in the country for traffic congestion, to promote Advil Congestion Relief. Chicago Bears legend and Pro Football Hall of Famer Richard Dent presided over the giveaway of the equipment and 100 new bikes last week. The company is running ads for the brand under the tagline “The Right Relief for the Real Problem, and will be holding similar events in communities around the country as part of its Advil Congestion Relief Project this winter. Visitors to the campaign website, CongestionReliefProject.com, can share their community's congestion relief needs for a chance to win $30,000 towards local congestion relief efforts.

“We are passionate about finding the right relief for the real problem for consumers wherever they need it, from their noses to their communities,” said Kristin Shea, franchise head for upper respiratory and allergy at Pfizer Consumer Healthcare. “We're excited to be hitting the road with the Advil Congestion Relief Project this cold and flu season and look forward to seeing the stories our consumers will share with us about their communities.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.